Related to ICR to Use AB Sciex Mass Spec System in Cancer Metastasis Research

• Does Clinical Success Mean Commercial Success for Cancer Vaccines?
  Getting insurers to pay for immunotherapies and keeping doctors more informed are key to market growth.
  
• Vaccine Isotype Seems to Affect Clinical Outcome in Blood Cancer Trials
  New results presented at ASH will impact production of autologous immunotherapies.
  
• Avastin Label Changes Reignites Debate: Is OS or PFS the Better Regulatory Endpoint?
  A recent panel discussion set the stage for defining standards for drug approval as separate from those for treatment decisions.
  
• A Little Mass Spec Goes a Long Way
  Review of a new method for the discovery of catalytic reactions shows its importance for also finding more optimal catalysts.
  
• How Provenge Laid the Groundwork for Developing and Regulating Cancer Vaccines
  FDA’s recently issued guidelines pull from more than 20 years of research and clinical experience.
  
• Immune Response Markers for Cancer Vaccines Paint a Clearer Picture
  In trying to understand what constitutes an effective immune response, researchers find it’s all about T cells.
  
• Sculpting the Right Epitope
  Researchers discuss a new form of antibody-based therapy utilizing binding mechanisms that mimic TIMPs.
  
• Leveraging the Cancer Transcriptome for New Drug Targets
  New analytical tools are advancing research efforts.
  
• Why Biomarker Discovery Is Hard
  Differentiating which markers are in the driver’s seat and which are along for the ride is key.
  
• Harvard Professor Rides Genomics' Third Wave
  New Firm Aims to Advance Personalized Medicine through Precision Diagnostics
  
• Will Less SOX2 Lead to Brain Cancer Getting Cold Feet?
  PLK1 level is elevated in glioblastoma multiforme, and its inhibition restricts the growth of brain cancer cells.
  
• Clinical Application of miRNAs Remains a Ways Off
  When and if its time comes, prognostic tests will likely be first.
  
• A SPA for PMTs
  Researchers propose a SPA strategy that can be successfully implemented to identify novel and specific inhibitors of PMTs.
  
• Olympic Anti-Doping Goes for Gold
  Mass spec and imaging are among the tools antidrug testers use to catch up with the cheaters.
  
• Leveraging Synthetic Lethality for Cancer Therapeutics
  Researchers investigate a class of therapeutics that could short-circuit cancer cells at the molecular level.
  
• Oncogene Addiction: Real or Not?
  Emerging documentation is starting to address that question and increase understanding of process.
  
• LAVAgel for Protein Diagnostics
  Researchers introduce a microfluidic, single-channel, multistage immunoblotting strategy toward scalable protein isoform analysis.
  
• End-Running Cancer Resistance to Targeted Therapies
  Overcoming resistance may require an assault on multiple fronts.
  
• A Cyber War on Cancer
  New strategies are hoping to put an end to the war that Richard Nixon declared four decades ago.
  
• Synthetic Degrons Play The N-End Game
  The Boc₃Arg moiety may provide a general strategy to construct inhibitors that induce targeted protein degradation.